Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ependymin-related protein 1 (EPDR1) is a conserved, glycosylated lysosomal protein found in vertebrates, including humans. Structurally, EPDR1 adopts a dimeric LolA/EPDR fold with deep hydrophobic grooves, suggesting a function in lipid binding or transport, particularly in the context of lysosomal lipid metabolism or as a lipid activator protein[1][3]. It exhibits sequence and structural homology to bacterial lipoprotein transporters (LolA/LolB), but its precise physiological substrates remain unidentified[1][3]. EPDR1 is implicated in modulating lysosomal glycosphingolipid-processing enzymes and has a role in cellular metabolism, including positive regulation of glucose-stimulated insulin secretion in pancreatic β-cells[7]. In disease, EPDR1 expression and genetic variants are associated with colorectal cancer, metabolic dysfunction, and glaucoma, but no direct small molecule inhibitors or drugs targeting EPDR1 are known at present[5]. The protein is not currently classified as a classical therapeutic target such as a receptor or enzyme.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ependymin-related protein 1 (EPDR1).